TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03568214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
Study: NCT00638677

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol
Description: Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol + BB12
Description: Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Xylitol
Description: Xylitol+BB 12 delivery with a pacifier max until 2 years
Study: NCT01520506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien OneShot™ System
Description: Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
Study: NCT02762916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selfmanage with the help of telemedicine program
Description: The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme
Study: NCT01883258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval training
Description: Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous moderate intensity exercise
Description: Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
Study: NCT03506152

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Procalcitonin
Description: Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Procalcitonin
Description: Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
Study: NCT02609854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Medicine (SAM)
Description: Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Device
Description: Inactive ultrasound device
Study: NCT03660553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: 0.40 units/kg body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: 0.20 units/kg body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: 0.20 units/kg body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: 0.20 units/kg body weight
Study: NCT02794168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS203
Description: Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT00448409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax
Description: 11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax
Description: 11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
Study: NCT00117845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (Ontak)
Description: Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
Study: NCT02972463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Y

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Y

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Y

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01836653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT04530617

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camostat Mesilate
Description: Tablets
Study: NCT01836653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT01845220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli Sprout Extract
Description: 150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80% acetone
Study: NCT06248554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles
Study: NCT03675178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anerning particle
Description: Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
Study: NCT02216617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere, Cisplatin, Afatinib
Study: NCT01709747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: Opioid for chronic pain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable Implantable pump
Description: Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone
Study: NCT01828073

Intervention type: DRUG
Intervention: Raltegravir
Description: No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.

Intervention type: DRUG
Intervention: Raltegravir
Description: No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
Study: NCT04327076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using robot system of endotracheal intubation and airway cleaning
Description: 1. Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~2. Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~3. During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically.
Study: NCT04530617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camostat Mesilate
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemisia Annua Leaf
Description: Tea bags

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemisia Annua Leaf
Description: Tea bags
Study: NCT00157677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D-dimer testing
Description: Uniform D-dimer use

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D-dimer testing
Description: Selective D-Dimer use
Study: NCT02958917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo controlled
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled
Description: This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
Study: NCT02944149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal ligation by minilaparotomy
Description: Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tubal ligation by minilaparotomy
Description: Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
Study: NCT03312634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene was taken orally once daily at approximately the same time each day following a meal.
Study: NCT00988806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosimendan
Description: Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Study: NCT05202886

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver from deceased donors
Description: Liver donors photographed
Study: NCT03208010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Intervention
Description: * Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~* Specific goals set for weight loss and physical activities~* Fitbits provided for monitoring physical activity goals~* Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~* 15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: * Monitoring by existing personal physicians~* Feedback on lab results~* Referrals to physicians or clinics, if needed~* Diabetes prevention educational materials
Study: NCT04950647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurazone Group 1
Description: Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroketazine Group 2
Description: Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
Study: NCT03827096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of human autologous MSC 3P in 1.5 ml
Description: During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
Study: NCT00966134

Intervention type: OTHER
Intervention: exposure to high altitude
Study: NCT02083900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Banana Leaf Dressing
Description: Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocolloid Dressing (DuoDERM CGF)
Description: The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
Study: NCT01702311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedtime insulin Aspart (Novolog)
Description: Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
Study: NCT00495313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: COL-101, QD plus metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 40 mg with metronidazole QD
Study: NCT04428853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iyengar yoga
Description: different yoga postures including warm up, cool down and meditation that incorporate 75 minutes of training
Study: NCT02922322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Group
Description: The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
Study: NCT00551811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933-AAA
Description: SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
Study: NCT04660604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston Technique®
Description: Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
Study: NCT04127890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ELO Water
Description: oxygen-enriched water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drinking water
Description: bottled drinking water
Study: NCT03836989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation device (tens unit)
Description: An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical stimulation device (tens unit)
Description: An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
Study: NCT00681746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C) flumazenil
Description: Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)